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ABSTRACT
Expression of the lysozyme gene is a marker for the differentiation of macrophages, lysozyme
transcription being gradually increased during maturation. We have analyzed the fine structure and
function of two macrophage-specific enhancer elements of the chicken lysozyme gene (E-2.7 kb
and E-0.2 kb). Both increase their activities upon LPS induction, both contain multiple binding sites
for similar or identical nuclear factors and both can be divided into two functional modules. For
the E-0.2 kb enhancer we found a synergistic activity of the modules to be dependent on their distance.
Binding sites for nuclear proteins within enhancer E-0.2kb overlap substantially with the previously
identified progesterone/glucocorticoid receptor binding site, which is required for steroid induction
of lysozyme transcription in the oviduct.
INTRODUCTION
One of the main contemporary challenges in molecular genetics is the elucidation of the
mechanisms underlying tissue specific gene expression. Several tissue specific promoter
and enhancer elements have been identified (1). Many of the model systems analyzed are
limited in that only mature cells or tissues are available for testing, whereas gene regulation
may involve a multi step process during differentiation from precursor to mature cells.
The haematopoetic cell population is generated by one of the few differentation pathways
which can be studied step by step in vitro as well as in vivo. One of the cell types generated
in this system is the macrophage cell. Expression of the lysozyme gene is a specific
differentiation marker, being gradually turned on during maturation of macrophages (2).
In addition to this constitutive macrophage expression, the chicken lysozyme gene is
inducible by steroid hormones in the tubular gland cells of the oviduct (3).
Three macrophage-specific enhancer elements of the chicken lysozyme gene have been
identified, one each at -6.1 kb (4), -2.7 kb (5) and -0.2 kb (5) upstream of the
transcription start site. The latter two elements are referred to here using the abbreviated
forms E-2.7 kb and E-0.2 kb according to their positions. Furthermore, two silencer
elements which are specifically inactive in mature macrophages (S-2.4 kb and S-0.25 kb),
and one which is active in all cell types tested (S-1.0 kb) have been described (5, 6). Steroid
induced expression in the oviduct is mediated by at least two different hormone responsive
elements, one at -200 bp (7) and one at -1.9 kb (8).
Here we report the fine structure of the two macrophage specific enhancer elements
E-2.7 kb and E-0.2 kb, their functional activity and their capacity to bind nuclear proteins.
The binding pattern in the multifunctional enhancer E-0.2 kb, which also contains functional
steroid receptor binding sites (7), suggests a competition between steroid receptors and
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The identity of the recombinant plasmids was confirmed by restriction mapping and dideoxy-
sequencing using the Sequenase-kit from USB.
The plasmids pICfrag21 and pUClys-280/+15 were created by inserting the
HindIHI/BglIH-lysozyme gene fragment from -2.71 kb to -2.54 kb and the HindIHI/XhoI-
fragment carrying the lysozyme-promoter (-280 to + 15) from plysCATA -280 (5) into
the corresponding sites in the polylinker of pIC20R (9).
Two series of different plasmids containing subregions of lys E-0.2 kb were used, all
of which are derivatives of the plamids pBLCAT2 (10) or plys-208/-67a tkCAT (5).
One series contains a spacer of varying length between lys -67/- 161 and lys - 162/-208
in front of tkCAT. This series was constructed by introducing a 20 bp synthetic
oligonucleotide containing recognition sites for SnaBI, Stul, NruI and Sall into the natural
RsaI-site in position -161 in plys-208/-67a tkCAT, and performing subsequent deletions
using these endonucleases. Plasmids with spacer-lengths of 5, 8, 10, 13, 15, 17 and 20
bp were constructed.
The second series contains various combinations of the lysozyme fragments from -208
to -162 and - 161 to -67 in front of the tkCAT-fusion gene. These plasmids were
constructed from a subclone of lys -67/-208 in pUC 18, of lys -95/-208 in pUC 18,
of plysCATA208 and pBLCAT2 (10). Selected lysozyme sequences were inserted in
antisense direction in front of the tk-promoter to test them directly for enhancer-
characteristics.
pE-0.2-1 was generated by ligating the lysozyme BamHI/AccI fragment from pUC
lys -208/-95 into the BamHI site of pBLCAT2.
pE-0.2 -2 contains the lysozyme sequences from -208 to -162 as an RsaI/BamHI-
fragment cloned into the BamHI and filled-in Sall sites of pBLCAT2.
By cloning a blunt-ended HindIII/RsaI-fragment from pUClys -208/-67 harboring the
region from -161 to -67 into the filled in BamHI- or HindIII-site of pBLCAT2 or the
BamHI-site of pE-0.2 -2, we obtained the plasmids pE-0.2-3, -4, -5, -6 and -2 x 3.
For a double insertion of the distal domain of E-0.2 kb this sequence was cut out of
pE-0.2 -2 with BamHI and Hindu, filled in and re-inserted into the blunt-ended HindIll
site of the same plasmid (pE-0.2-2x2).
For pSVtkCAT and E-2.7 constructions see Steiner et al., 1987 (5).
Nuclear Extract Preparation
The nuclear extracts were prepared as described (11-13). Subconfluent cells were harvested
from about 60 culture dishes (15 cm in diameter) and washed in phosphate buffered saline.
All following manipulations were performed at 0°C using precooled solutions, tubes and
Figure 1. DNaseI protection assay on the E-2.7 kb (A) and the E-0.2 kb enhancer (B). The upper (upper) and
lower strands (lower) were 3' end-labelled and digested with DNaseI in the presence of HD1I nuclear extract
(+) or without nuclear extract (-). The G+A sequencing products are shown as molecular weight markers.
The shaded diagram on the right depicts the footprinting pattern achieved, boxes indicate protected sequences,
arrows show positions of strong DNaseI hypersensitivity caused by nuclear extracts and horizontal lines poin
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centrifuges. The pelleted cells were suspended in five packed cell volumes (PCV) of buffer
A' (10 mM Hepes/KOH (pH 7.6), 10 mM KCI, 0.15 mM spermine, 0.5 mM spermidine,
1mM EDTA, 0.5 mM DTT) and allowed to stand on ice for 10 min. The cells were pelleted
by centrifugation and suspended in 2 PCV. The cells were broken by homogenization in
a glass-glass dounce homogenizer. After addition of one-tenth volume of buffer B' (1OmM
Hepes-KOH (pH 7.6), 1M KCl, 0.15 mM spermin, 0.5 mM spermidin, 1mM EDTA,
0.5 mM DTT) the nuclei were pelleted by centrifugation (2400 rpm; 10 min). This pellet
was used to prepare the nuclear extract as described (12) with the modification that the
volume of nuclear lysis buffer was 1 PCV and that the precipitated nuclear proteins were
dissolved in 1/10 PCV of the dialysis buffer. The opaque nuclear extract with a protein
concentration of 5-20 mg/ml (Biorad protein assay) was frozen in small aliquots in liquid
nitrogen and stored at -85°C.
DNaseI-Footprinting and Band Shift Assays
To obtain probes labelled on one strand the plasmids pICfrag2l and pUClys -280/+15
were cut with EcoRI and labelled as described (14). The footprint reactions were performed
according to Cereghini et al., 1987 (15) with the described modifications (14). The following
blunt ended, double stranded oligonucleotides were used: lysozyme sequences -208/- 162,
-193/-180, -146/-123, -125/-93, -96/-66; SV40 core: GTTAGGGTGT-
GGAAAGTCCCCAG; SPI SV: CGACTGATCAGTTCCGCCCATTCTCCGCCCCAG
(with AccI/BamHI sticky ends); Spl dhfr: CTTGGTGGGGGCGGGGCCTAAGCTG
(16); AP4: GATCACCAGCTGTGGAAT (17).
Band shift assays were performed in a total volume of 10 yl containing: 250 ng poly(dIdC)
(Pharmacia), 25 ng denatured calf thymus DNA, 5% glycerol; 25 mM Hepes/KOH pH
= 7.6, 25 mM KCI, 5 mM MgCl2, 0.4 jig nuclear extract and 32P-labelled double
stranded oligonucleotide (30,000 to 40,000 cpm). The nuclear extract was preincubated
for 15 min on ice before addition of the labelled probe. After further 20 min incubation
on ice the samples were loaded directly on a 5% acrylamide gel (acrylamide:bisacrylamide
ratio of 79: 1 in 192 mM glycin / 25 mM Tris buffer).
The gel was run for 1.5 hrs at 15 to 20 mA at +4°C, fixed, dried and autoradiographed.
Cell Culture, Transfection and CAT-Assays
HD1 1 [=HBC1 =LSCC-HD(MC/MA1) (18)] and DU249 (19) cells were maintained in
DME-medium (Biochrom) supplemented with 8% fetal calf serum, 2% chicken serum,
100 units/ml penicillin and 100 jig/ml streptomycin. All transfection experiments were
done in triplicate and confirmed in a second series of tests. Transfections were carried
out as described (5) with the help of an automated 'precipitator' (20). LPS treatment of
HD1 1 cells was done by applying 0.1 tg/ml LPS to the dishes at 22hrs after transfer.
All cells were harvested 2d after DNA transfer and assayed for CAT activity or for mRNA
amounts (5).
Figure 2. Competitions of the footprints on the enhancer E-2.7 kb and E-0.2 kb. Footprint reactions without
nuclear extract (-) and with HDII nuclear extract either without competitor (/) or with double stranded
oligonucleotides (1), (2), (3) or (4) in amounts of 0.5 pmole (left lanes) or 2.5 pmole (right lanes). Vertical lines
indicate the positions of protected regions, whereas the dots point out competed footprints. The following 3'
end-labelled DNA fragments were used: upper strand of E-2.7 kb (A), upper strand of E-0.2 kb (B) and, for





Figure 3. Gel shift experiments with lysozyme (lys -96/-66) and SpI (SpI dhfr) oligonucleotides. HD1 1 nuclear
extract was assayed for specific DNA binding activity. Competition experiments were done using two different
concentrations (0.1 pmole and lpmole in the first and second lane, respectively) of double stranded oligonucleotides
lys -96/-66, Spl SV and Spl dhfr. The AP4 oligonucleotide was used at a concentration of 1 pmole. The









Figure 4. Comparison of HD1 1 and DU249 nuclear extracts in footprint reactions. The lower strand of E-2.7
kb (A) and the lower strand of E-0.2 kb (B) were 3' end-labelled and incubated with HD1 1 (HD) or DU249
extract (DU) and DNase I digested. For comparison footprint reactions without nuclear extract (-) and G+A
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Figure 5. Competition of the liver cells specific footprint on the E-0.2 kb enhancer. Footprint reactions with
DU249 (DU), with HD1 1 (HD) or without (-) nuclear extract are shown. Competitions with unlabelled double
stranded oligonucleotide 1 or 5 (-208/-162 or - 193/-180 lysozyme sequences; see Figure 2D) were carried
out with 3-10 pmole as competitor DNA [(1) and (5); (I) is without competitor DNA]. Vertical lines indicate
the footprint regions and the arrow heads point to hypersensitive sites.
RESULTS
Several Factors Bind to Both Enhancers E-2. 7 kb and E-O.2 kb
We have previously identified two macrophage specific enhancer elements upstream of
the chicken lysozyme gene (5). Sequences of about 150 bp each are required for optimal
function of both enhancer sequences. Since the size of these elements suggested the possible
presence of several binding sites for nuclear proteins, we carried out footprinting
experiments using total nuclear extracts. Nuclear extracts were purified from a chicken
promacrophage cell line (HD 11) in which both enhancer elements are functional (5).
Footprinting experiments on both enhancer sequences demonstrated the protection from
DNase I digestion of multiple regions (figure 1). Sequence analysis of both enhancer
elements has revealed a common sequence motif present several times in E-2.7 kb and
in E-0.2 kb (5). This motif is similar to the SV40 enhancer core sequence (21). Since
most of these sequence elements are protected from DNase I digestion in the footprinting
experiments (see figure 6), we tested for relationship between the bound proteins. We
used four different oligonucleotides to compete the protein binding in footprint reactions
(figure 2). Oligonucleotide [1] contains lysozyme sequences from -208 bp to -162 bp
including two core motif homologies; oligonucleotides [2] and [3], which correspond to
the regions -146 bp to -123 bp and -125 bp to -93 bp, respectively, contain one core
motif each. The oligonucleotide [4] contains the original SV40 core sequence [SV40
sequences 233 to 255; BBB system (22)]. The footprint competitions show that the proteins
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(figure 2). Although differences in binding efficiences are seen-each oligonucleotide
showing the best competition for the footprint on its corresponding region-it is obvious
that all the 'core'-containing sequences show qualitatively identical competitor function
in comparison to footprints which are not changed, such as the footprint upstream of -217
bp (figure 2C), which lies within the silencer element S-0.25 kb (6) and the E-2.7 kb
footprints outside the 'core' sequence-containing region (E-2.7 kb sequences -2600 bp
to -2700 bp; figure 2A).
One of the footprint regions (sequences -90 to -74 ) in the E-0.2 kb enhancer could
only be detected quite weakly, and since the sequence resembles a Spl binding site (see
figure 6), we performed band shift experiments with lysozyme DNA -96/-66 (figure
3). One major shifted band can be seen in addition to several minor bands. All can be
competed specifically by the lysozyme sequence (-96/-66) and by two different Spl
binding sites [one from the SV 40 promoter (Spl SV) and one from the dihydrofolate
reductase gene (SpI dhfr)], except for one minor band. An AP4 binding site cannot compete.
This complex pattern of several shifted bands is typical for Spl as can be seen in the
reciprocal experiment (figure 3): the labelled Spl dhfr DNA shows the same pattern of
shifted bands which is competable by itself, the Spl SV and the lys -96/-66
oligonucleotides. The SpI and lys -96/-66 oligonucleotides differ only in their binding
affinities, that of the lysozyme sequence being weakest.
Tissue Specific Differences in Binding Patterns of Nuclear Proteins
In order to identify those regions of the lysozyme enhancers involved in binding tissue
specific proteins, we compared nuclear extracts from a chicken liver cell line (DU249,
in which the lysozyme gene is inactive) with the HD1 1 promacrophage extract. Some extract
specific differences can be detected for both enhancer elements in their promoter distal
parts (figure 4). The E-2.7 element manifests its specificity in HD1 1 specific hypersensitive
sites within the large footprint area between nucleotides -2635 and -2675 (figure 4A:
domain A). Cell type specific footprint patterns can be seen on the E-0.2 element between
nucleotides -155 and -192 (figure 4B: domain A). One HD1 1 specific footprint
(- 1551- 175) and one extended footprint caused by the DU249 extract (-180/- 192) are
evident (figure 4B).
The extended footprint seen in the region - 193 bp to - 180 bp with the DU249 extract
was also seen with an extract from another lysozyme negative cell line, HD3 erythroblasts
(Baniahmad, Steiner and Renkawitz, unpublished results). This footprint may be the result
of a single additional binding protein absent in HD1 1, or may reflect the binding of a
completely different set of binding proteins in each extract. To distinguish between these
two possibilities, we carried out footprinting reactions with the liver cell extract in the
presence of an excess of various competitor oligonucleotides (figure 5). As a control we
used the oligonucleotide -208/-162 (oligonucleotide 1, see figure 2) which covers the
liver cell-specific footprint plus both flanking footprints. Upon competition this complete
Figure 6. Regions of the E-2.7 kb and the E-0.2 kb enhancer bound by nuclear proteins. Binding sequences
as determined by footprinting and band shift experiments are boxed. DNA regions covered by the progesterone
(PR) or glucocorticoid (GR) receptors are indicated (1,22). Sequences with identical shading can compete each
other. The table lists all the lysozyme sequences (underlined) protected in footprint experiments (numbered E-2.7F1
to F5 and E-0.2F1 to F6) with their similarities (capital letters) to known transcription factor binding sites (see
text). AP3-C/EBP binding sequences are either taken from SV40 (26) or from polyoma (28). (+) and (-) indicate












Figure 7. Functional activity of E-2.7 kb enhancer derivatives. The E-2.7 element and subregions thereof were
cloned in front of tk CAT and transfected into HDI 1 (promacrophages) or DU249 (liver) cells. CAT expression
is normalized to the expression of tk CAT and enhancer activity of E-2.7 in HD 1I is set to 100%. Footprint
regions Fl to F5 are shown. The function of domains A and B is discussed in the text.
region becomes DNaseI sensitive. However, competition with the short oligonucleotide
- 193/-180 (oligonucleotide 5, see figure 2), which covers only the liver cell specific
footprint, generates a cluster of DNase I-sensitive sites in this central region without affecting
the flanking footprints. This pattern of protected regions is identical to that achieved with
the macrophage extract in the absence of competitor (figure 5). Therefore, we conclude
that this extract-specific difference in the footprint patterns is caused by an additional factor
binding on the DNA between -193 bp and -180 bp upstream of the transcriptional start
site, this factor being absent in promacrophage nuclei.
Figure 6 summarizes the footprinting results described above. For each of the lysozyme
sequences protected in the footprinting experiments (E-2.7F1 to F5 and E-0.2 Fl to F6)
similarities to other nuclear factor binding sites are indicated. E-2.7F1 contains two repeats
of the GCN4 protein binding site which is the yeast homologue to transcription factor API
(23). This particular binding site has only a low affinity for GCN4 (24), but since it is
repeated, both may function in a synergistic manner. E-2.7F2 is quite similar to the SV40
PU-box, which can be bound by a lymphoid specific protein (25). E-2.7F3 contains a
strong binding sequence for GCN4-AP1 (24). Sequences in E-2.7F4, E-0.2F4 and F5 are
similar to each other (lys.cons.) (5) and to the 'core' enhancer sequence (21). This motif
can be bound by the AP3 protein (26,27) or by C/EBP (28). In addition E-0.2F4 is similar
to a 'half binding site' of NFl (15). E-2.7F5 shows similarities to AP3-C/EBP and to
the 'octa'-sequence (29,30). AP3-C/EBP similaritiy is also seen with the footprint sequences
E-0.2F1 and F3 with F3 containing a CAAT-box, which is bound by C/EBP as well (31).
All of the footprint sequences with AP3-C/EBP similarity are competeable by the SV40
'core'-sequence (see above) which is recognized by AP3 (27). The footprint E-0.2F2
contains a sequence identical to the negative NRDI region of the human 13-interferon gene
(32) and E-0.2F6 contains a binding sequence identical to the Spl binding site of the human
U2 small nuclear RNA gene (33). In addition to the regions defined by the footprinting
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experiments with whole nuclear extracts the glucocorticoid and progesterone receptor
binding sites are shown on the E-0.2 enhancers (7,34).
Since tissue specific footprinting patterns are seen on the distal halves of each enhancers,
we carried out functional tests both on the complete enhancers and on isolated enhancer
elements.
Tissue Specific Enhancer Actvity is Achieved by a Combinatorial Effect ofEnhancer Modules
Having found multiple binding sites for similar nuclear factors on both enhancers, we wanted
to know whether or not all of these sites are required for function, and if interaction between
sites could be detected. We cloned several enhancer subfragments in various orientations
and combinations upstream of the thymidine kinase (tk) promoter, which in turn was fused
to the chloramphenicol acetyl transferase (CAT) gene (10). The resulting contructs (figures
7 and 8) were transfected into chicken liver cells (DU249) and chicken promacrophages
(HD1 1), and cell extracts were analyzed for CAT-activity. To normalize for different
transfection efficiencies into these two cell lines, we used a plasmid carrying the SV40
enhancer upstream of the tkCAT fusion gene as a standard. Both lysozyme enhancers
showed about half of the SV40 enhancer activity in HD1 1 cells (data not shown), whereas
they remained inactive in DU249 cells (figures 7 and 8).
The E-2.7 enhancer either intact, or with a 5' deletion (2.7-1), which does not affect
the footprint region, shows full enhancer activity in promacrophage cells and low activity
in liver cells (figure 7). The two enhancer parts (2.7-2 and 2.7-3) show very different
activities: the distal domain (A) is clearly active by itself, but the proximal domain (B)
is not. Only the combination of both (2.7-1) leads to full activity in HD1 1 promacrophages.
Similarly, dissection of the E-0.2 enhancer demonstrates the function of two domains (figure
8). 3' deletions up to domain A (construct 0.2-2) show a progressive loss of enhancer
activity indicating the requirement of domain B for enhancer function. Neither domain
A nor B is active in isolation. Duplication leads to strong activity of domain A (0.2-2 x2),
whereas domain B (0.2-2 x 3) remains inactive. Interestingly, duplication of 'A' shows
wildtype enhancer activity in HD1 1 promacrophages, but does not show the tissue
specificity: clear enhancer activity is seen even in liver cells (figure 8A).The recombined
enhancer with both halves arranged in a head to head orientation (construct 0.2-4)
maintained wildtype enhancer activity and tissue specificity. Upon separation of the two
halves by 23 bp with the distal domain in sense orientation (construct 0.2-5) or by 46
bp with the distal domain in anti-sense orientation (construct 0.2-6) enhancer activity
was considerably reduced.
In order to confirm that the observed CAT-activities reflect the amount of correctly
initiated RNA, RNase mapping experiments were carried out on RNA generated after
transfecting selected constructs in HD1 1 cells. These experiments confirmed the results
of the CAT-assays (figure 8B).
To examine in more detail the observed disruption of enhancer activity following
separation of the enhancer halves, we inserted linkers of different length (5, 8, 10, 13,
15, 17 and 20 bp) between positions -161 bp and -162 bp. CAT-activities recorded
after transfection into HD1 1 cells are shown in figure 9. Insertion of 5 bp reduced enhancer
activity considerably, with a further reduction caused by an 8 bp spacer. However, a spacer
of 10 bp leads to an increase in enhancer activity, presumably allowing the proteins bound
to the two enhancer halves to be positioned in a three dimensional arrangement similar
to that in the wildtype enhancer. This result indicates the requirement for a certain distance















Figure 8. Functional activity of E-0.2 kb enhancer derivatives. E-0.2 recombinant sequences were cloned in
front of tk CAT and transfected into HD1 1 or DU249 cells (see legend for figure 7). A. CAT activity. Footprint
regions Fl to F6 and binding sites for the progesterone (PR) and glucocorticoid (GR) receptors are indicated.
B. RNase mapping of selected constructs after transfection into HDl 1 cells. Lane (P) is the untreated probe,
lane (M) end-labelled marker DNA and lane (tRNA) the probe hybridized with tRNA and digested with RNase
A and T1. (C) is a labelled control DNA fragment carried through the RNase mapping procedure to judge complete
recovery of nucleic acids. (+ 1) indicates the position of correctly initiated RNA and (P) the size of the probe.
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resulted in levels which, although suggestive of a periodicity in activities, lie within the
deviation of the experiment.
We conclude that activity of the 150 bp E-0.2 kb enhancer is a result of a synergistic,
orientation independent interaction between domains A and B, and that tissue specificity
is achieved by the combinatorial effect of both domains.
Both Enhancer are LPS Inducible
Since lysozyme expression is gradually increased during macrophage differentiation (2)
and since both enhancer elements show a higher activity in primary mature macrophages
as compared to HD1 1 promacrophages (5) we analyzed the enhancer activity in LPS treated
HD 11 cells. LPS is known to activate and to induce developmental changes in macrophages
[for review see (35)]. To test, whether the activity of the lysozyme enhancer elements
is sensitive to LPS treatment of the cells, we carried out DNA transfer experiments in
the presence of LPS. Transient expression of pE-0.2 tk CAT and pE-2.7 tk CAT in HD 1I
cells was clearly induced by LPS, whereas the ptkCAT control plasmid was not induced
(figure 10).
DISCUSSION
The complex regulation of the chicken lysozyme gene by steroid hormones in the oviduct
and by the maturation of macrophages is achieved by the combined action of several
enhancer, silencer and steroid responsive elements [for review see (36)]. Whether all of
these elements act independently on the promoter or whether they interact with each other
remains to be shown. Here we describe the detailed analysis of both lysozyme gene-
enhancers E-2.7 kb and E-0.2 kb, which consist of several protein binding sites coinciding
with functional modules. Some of the binding proteins are tissue-specific, others are present
in liver cells as well as in promacrophages. Such a concomitant binding of cell-type specific
and ubiquitous factors is also found in other enhancer elements, for example in that of
the mouse cl-antitrypsin gene (37). The lysozyme enhancers E-2.7 kb and E-0.2 kb together
contain six 'core' motif homologies which are completely protected by nuclear proteins
from digestion with DNaseI (figure 6). Competition experiments demonstrate the importance
of the 'core' homology in the binding, as cross-competition is a property of all protected
regions which share only these sequences. This indicates that proteins with at least similar
DNA-binding domains recognize different parts of both enhancers E-2.7 kb and E-0.2
kb. Although we find multiple similar binding sites, the enhancer domains show different
activities, and specificities and therefore the binding proteins may be different. It is possible
that the binding proteins described here are related to the previously characterised factors
AP3 or C/EBP (26,28), although this has to be proven by analyzing the respective close
contact sites on the recognition sequences. A similar puzzling situation of cell type specific
and unspecific effects caused by the same binding sequence has been found for the octamer
sequence [for review see (38)]. Both the expression of B-cell specific and of 'housekeeping
genes' can be driven by octamer factors.
Characterization of the protein-binding sites has prompted us to dissect E-0.2 kb into
two domains. Although neither of these domains has strong enhancer activity alone as
a single copy, duplication of the distal domain (-208/-162) results in an activity similar
to that of the complete enhancer, but without its tissue specificity. Only the combinatorial
effect of both domains leads to wildtype activity and specificity. This was also shown for
the two domains of the E-2.7 kb enhancer (figure 7). The synergistic effect of enhancer
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Figure 9. CAT activities of spacing mutants of the E-0.2 kb enhancer. Different spacer lengths were inserted
between nucleotides - 162 and - 161 of the E-0.2 kb enhancer and tested for their effect on enhancer activity
upstream of tk CAT. CAT activities achieved after transfecting HD1 I cells in triplicate experiments are shown
with standard deviations, activity of tk CAT without enhancer sequences is indicated by the arrow.
rearranged modules. Investigation of the requirement for a particular distance of the two
domains indicated a dependence of enhancer activity on the relative position of the modules.
Similar effects of the stereospecific alignment on the efficiency of transcription regulating
elements has been shown for the SV 40 enhancer (39) or for the interaction of the
glucocorticoid receptor and the CACCC-protein (14). In each case optimal activity was
only observed after introduction of multiples of a complete helical turn of the DNA between
the protein binding sites. In the case of lys E-0.2 kb, we observe a strong decrease of
activity upon introducing additional nucleotides between its two domains with a peak of
increased activity upon insertion of 10 bp. A synergistic interaction of the bound proteins
in this constellation would be indicative of a bending of DNA between the two domains,
a flexible protein domain and/or the involvement of a 'bridging protein' that mediates the
interaction of the DNA-bound factors and could confer the flexibility to the whole system.
Participation of non-DNA-binding proteins in transcription regulation has been shown in
some cases (40-44).
Domain structures such as those described here are also found in other transcription
regulatory elements and seem to be a general phenomenon (37,45,46). A modular structure
may be adapted during evolution to a variety of regulatory processes by using various
combinations of a limited number of different binding sites.
Clear tissue-specific differences in the binding pattern of liver cell and promacrophage
extracts were observed between -2675 bp and -2635 bp and - 192 bp and - 155 bp
(figure 6). The regions of both enhancers (domain A) harboring these binding sites show
enhancing activity by themselves or upon duplication in promacrophage cells (figures 7
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Figure 10. LPS induces enhancer activity. Both enhancer constructs pE-0.2 tk CAT (E-0.2) and pE-2.7 tk CAT
(E-2.7) were transfected into LPS treated or untreated HD1 1 promacrophages. CAT activities are compared to
the expression at ptk CAT (tk).
and 8). Whether the increase of enhancer activity during differentiation or during LPS
treatment involves one or several of these binding proteins remains to be shown. In the
case of E-0.2 kb it seems that liver cells contain an extra DNA binding protein in addition
to those found in the promacrophage line. A possible negative effect of this protein is
also suggested by the remarkable similarity of the binding sequence with the negative
regulatory domain I (NRDI) of the human fl-interaction gene (32).
The E-0.2 kb enhancer of the chicken lysozyme gene can also bind steroid-hormone-
receptors in vitro, and is involved in the hormonal control of lysozyme synthesis in the
oviduct [(7) and figure 6]. Since the receptor binding sites are overlapping with the nuclear
factor binding sites described in this paper, a degree of interference between regulatory
proteins may be postulated, possibly involving a block of expression in the oviduct being
overcome by a steroid stimulus. In other cells, although the appropriate receptors are present,
nuclear factors might prevent binding of steroid receptors. Such a tissue specific steroid
regulation has recently been demonstrated for the chicken ovalbumin gene (47). The E-0.2
kb enhancer evidently acts as a multifunctional element: it contributes to the constitutive
gene expression in macrophages and the hormone-induction in the oviduct, the regions
mediating these effects being structurally, and probably functionally, highly integrated.
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